The idea of HER2-ultralow breast cancers (defined as IHC 0 with membrane staining in ≤10% of tumor cells) was lately conceptualized by the DESTINY-Breast06 trial presented at the 2024 annual ASCO conference (10). Here, ERBB2 is linked to breast carcinoma.